SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Researchers Stumble Upon Potential Key to Slow DMD
Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.
July 5, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
AstraZeneca, Daiichi Sankyo Move the Bar in Metastatic Breast Cancer
Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.
June 6, 2022
 · 
3 min read
 · 
Alex Keown
Courtesy of Getty Images
Drug Development
Celebrities are Bringing Awareness to Breast Cancer
Celebrities’ struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health’s elacestrant are on the horizon.
May 20, 2022
 · 
3 min read
 · 
Hayley Shasteen
Drug Development
Mersana Enters Busy Gastric Cancer Space with Orphan Drug Designation
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
May 19, 2022
 · 
2 min read
 · 
Hayley Shasteen
Courtesy of Getty Images
Drug Development
AstraZeneca and Daiichi Sankyo Move into Earlier Treatment Space with Enhertu
AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval for an earlier form of breast cancer from the U.S. Food and Drug Administration.
May 5, 2022
 · 
2 min read
 · 
Hayley Shasteen
Business
AstraZeneca and Daiichi Sankyo Score Priority Review in NSCLC
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
April 19, 2022
 · 
3 min read
 · 
Mark Terry
Leon Neal/Getty Images
Business
AstraZeneca Picks Up Another Oncology Asset in Quest to “Completely Replace” Standard
AstraZeneca has penned a deal with Harbour Biomed for its bispecific antibody HBM7022, which is intended to eliminate tumors in oncological patients.
April 7, 2022
 · 
3 min read
 · 
Hayley Shasteen
Courtesy of Daiichi Sankyo
Business
Daiichi Sankyo is Embarking on Mission Possible
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
March 5, 2022
 · 
5 min read
 · 
Heather McKenzie
Drug Development
Green Lights and Setbacks: Clinical Trial Updates for Feb. 21-25
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week’s clinical trial news.
February 25, 2022
 · 
5 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
FDA
INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
June 5, 2023
 · 
12 min read
Business
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
June 5, 2023
 · 
13 min read
Pharm Country
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA
May 25, 2023
 · 
27 min read
Pharm Country
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
April 20, 2023
 · 
6 min read
Business
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
March 30, 2023
 · 
2 min read
Drug Development
Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials
March 19, 2023
 · 
17 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
March 6, 2023
 · 
24 min read
Drug Development
ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
March 6, 2023
 · 
25 min read
Pharm Country
U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen
February 16, 2023
 · 
2 min read
Pharm Country
TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor
February 1, 2023
 · 
14 min read
Load More